Further investigations into ARRDC3 and related arrestin family members, and in particular their relationship to TRP53, are certainly warranted, and may uncover new therapeutic avenues or key regulatory avenues that could bypass defects in TP53 for cancer therapy. This evidence concerns the gene TP53 and cancer.